NEW YORK, Aug. 02, 2024 (GLOBE NEWSWIRE) -- __________________ WHY: Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024. Lifecore describes itself as an "integrated contract development and manufacturing organization in the U.S. and internationally." A class action lawsuit has already been filed. If you wish to serve as lead plainti ...

NEW YORK, Aug. 1, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024. Lifecore describes itself as an "integrated contract development and manufacturing organization in the U.S. and internationally." A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Co ...

LOS ANGELES, Aug. 1, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ: LFCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Per ...

SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Lifecore Biomedical, Inc. (NASDAQ: LFCR) securities between October 7, 2020 and March 19, 2024, both dates inclusive (the "Class Period"), have until September 27, 2024 to seek appointment as lead plaintiff of the Lifecore Biomedical class action lawsuit. Captioned Carew v. Lifecore Biomedical, Inc., No. 24-cv-03028 (D. Minn.), the Lifecore Biomedical class action lawsuit charges Lifecore ...

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR) in the United States District Court for the District of Minnesota on behalf of all persons and entities who purchased or otherwise acquired Lifecore securities between October 7, 2020 and March 19, 2024, both dates inclusive (the "Class Period"). Investo ...

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of Lifecore Biomedical, Inc. ("Lifecore") (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"). For more information, submit a form at Lifecore Biomedical, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@ber ...

If you bought shares of Lifecore between October 7, 2020 and March 19, 2024, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm's website at www.holzerlaw.com/case/lifecore-biomedical/ to learn more. Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, and 2023, dedicates its practice to vigorous ...

If you suffered substantial losses and wish to serve as lead plaintiff of the Lifecore Biomedical class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449- 4900 or via e-mail at info@rgrdlaw.com. The Lifecore Biomedical class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Lifecore Biomedical maintained defi ...

About Lifecore Biomedical The RSU award will vest and be settled as to 25,000 shares of the RSU on May 20, 2024 and as to 100,000 shares of the RSU on each of the first five anniversaries of May 20, 2024 and is governed by a Restricted Stock Unit Award Agreement and the Inducement Plan. The PSU award will vest, if at all, based upon the Performance Price achievement within the five year performance period as compared to a range of ten prices from $7.50 per share to $35.00 per share. The Performance Price is ...

On May 10, 2024, the Company also entered into the Seventh Amendment to the ABL Loan Agreement with its ABL lender to execute a "first-in, last-out" tranche of revolving loans under the ABL Loan Agreement (the "FILO Amendment"). While not increasing the overall revolver commitment of $40 million, the FILO Amendment provides for up to approximately $2.5 million of incremental revolving loan capacity to the Company, subject to a variable cap, without changing the collateral. In connection with the FILO Amendm ...